Thursday, 22 Jun 2017

Unknown content type

Bone Turnover Markers in Practice: A Guide for the Rheumatologist

Bone turnover markers (BTMs) have been eyed for decades as potential monitoring tools in osteoporosis.

However there have been difficulties with poor between-lab reproductivity, insufficiently controlled heterogeneity, and pre-analytical variability of the assays; making BTMs vastly unpopular amongst practicing rheumatologists.

Tildrakizumab, an IL-23 Inhibitor, is Successful in Plaque Psoriasis

Therapeutic options for cutaneous psoriasis (and psoriatic arthritis as well) are rapidly expanding.  Lancet has published the impressive results of two phase III trials of tildrakizumab, a IgG1 antibody against interleukin 23 p19, in patients with active chronic plaque psoriasis.

ACR/AAHKS Guidelines on Perioperative Management

The American College of Rheumatology has partnered with the American Association of Hip and Knee Surgeons to develop consensus-based guidelines for perioperative management of antirheumatic therapies for patients with rheumatic diseases who plan to undergo total joint replacement.

EULAR 2017 – Day 4 Highlights

Saturday was a day of big posters and special seminars at EULAR in Madrid.  In the morning, I passed on an interesting session on nailfold capillaroscopy led by Dr. M Cutolo and went to a JIA outcomes session. I reported on this in a video from day 4 (Saturday) called “Long-Term Comorbidities in JIA” – you can find it here.

Responder Criteria for Nonpharmalogical Treatment of Fibromyalgia.

Because of the subjective nature of fibromyalgia symptoms, tools for monitoring of disease activity and/or treatment assessment tools to evaluate effectiveness of nonpharmacological modalities are difficult to develop.

Concomitant Septic Arthritis and Crystalline Arthropathy

Researchers sought to describe the characteristics of patients with concurrent septic and crystal arthritis through a retrospective analysis of patients with the concomitant diagnoses between 1985-2015 at a university hospital in Spain.

EULAR 2017 – Day 3 Highlights

Friday was a mega-day in Madrid as this day all the late-breaking abstracts were presented, in addition to the bulk of high-impact podium presentations in several areas.

Here are the major presentations from several clinical areas.

Pregnancy in Lupus

Young patients with systemic lupus erythematosus (SLE) get diagnosed before they have completed their families. About 30 or 40 years ago, most rheumatologists were not recommending pregnancy for their lupus patients. However, in recent times, outcomes have considerably improved.

Herpes Zoster

Today during the comorbidities in RA session, Dr. Leonard Calabrese spoke about herpes zoster (HZ). Given the frequency of HZ in immunocompetent persons and the fact that patients with IMIDs carry at least twice the risk of developing HZ, it is important for rheumatologists to be informed about diagnosis, treatment and most importantly prevention of HZ.

Guselkumab for Active Psoriatic Arthritis

A double-blind, placebo-controlled, multicenter study aimed to evaluate efficacy and safety of a fully human monoclonal anti IL-23 antibody guselkumab, in patients with active psoriatic arthritis.  

The RheumNow EULAR Week in Review – 16 June 2017

Dr. Jack Cush reviews some of the highlights from the past week at EULAR 2017 - June 16, 2017.

Follow RheumNow's expanded coverage from EULAR 2017 in Madrid.

Gouts' Increasing Hospitalizations and Poor Management

Numerous studies have shown that gout hospitalizations have increased in the last decade. Also worrisome is a new studiy showing that patients admitted to the hospital are less likely to have received recommended urate-lowering treatment (ULT). (Abstract OP0262 - http://buff.ly/2roN7SF)